Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression

Xuehong Deng, Han Liu, Jiaoti Huang, Liang Cheng, Evan T. Keller, Sarah J. Parsons, Chang Deng Hu

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors. Although some patients respond well to the treatment, ∼10% of low-risk and up to 60% of high-risk prostate cancer patients experience recurrent tumors. However, the molecular mechanisms underlying tumor recurrence remain largely unknown. Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis. Further analyses revealed that two cyclic AMP-responsive element binding transcription factors, cyclic AMP-response element binding protein (CREB) and activating transcription factor 2 (ATF2), function as a transcriptional activator and a repressor, respectively, of NE-like differentiation and that IR induces NE-like differentiation by increasing the nuclear content of phospho-CREB and cytoplasmic accumulation of ATF2. Consistent with this notion, stable expression of a nonphosphorylatable CREB or a constitutively nuclear-localized ATF2 in LNCaP cells inhibits IR-induced NE-like differentiation. IR-induced NE-like morphologies are reversible, and three IR-resistant clones isolated from dedifferentiated cells have acquired the ability to proliferate and lost the NE-like cell properties. In addition, these three IR-resistant clones exhibit differential responses to IR- and androgen depletion-induced NE-like differentiation. However, they are all resistant to cell death induced by IR and the chemotherapeutic agent docetaxel and to androgen depletion-induced growth inhibition. These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.

Original languageEnglish
Pages (from-to)9663-9670
Number of pages8
JournalCancer Research
Volume68
Issue number23
DOIs
StatePublished - Dec 1 2008

Fingerprint

Activating Transcription Factor 2
Cyclic AMP Response Element-Binding Protein
Ionizing Radiation
Disease Progression
Prostatic Neoplasms
Androgens
Neuroendocrine Cells
docetaxel
Neoplasms
Radiotherapy
Clone Cells
Recurrence
Growth
Cyclic AMP
Cell Death
Transcription Factors
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2 : Implications for disease progression. / Deng, Xuehong; Liu, Han; Huang, Jiaoti; Cheng, Liang; Keller, Evan T.; Parsons, Sarah J.; Hu, Chang Deng.

In: Cancer Research, Vol. 68, No. 23, 01.12.2008, p. 9663-9670.

Research output: Contribution to journalArticle

Deng, Xuehong ; Liu, Han ; Huang, Jiaoti ; Cheng, Liang ; Keller, Evan T. ; Parsons, Sarah J. ; Hu, Chang Deng. / Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2 : Implications for disease progression. In: Cancer Research. 2008 ; Vol. 68, No. 23. pp. 9663-9670.
@article{692806f02a814867940bfdf03f45edef,
title = "Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression",
abstract = "Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors. Although some patients respond well to the treatment, ∼10{\%} of low-risk and up to 60{\%} of high-risk prostate cancer patients experience recurrent tumors. However, the molecular mechanisms underlying tumor recurrence remain largely unknown. Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis. Further analyses revealed that two cyclic AMP-responsive element binding transcription factors, cyclic AMP-response element binding protein (CREB) and activating transcription factor 2 (ATF2), function as a transcriptional activator and a repressor, respectively, of NE-like differentiation and that IR induces NE-like differentiation by increasing the nuclear content of phospho-CREB and cytoplasmic accumulation of ATF2. Consistent with this notion, stable expression of a nonphosphorylatable CREB or a constitutively nuclear-localized ATF2 in LNCaP cells inhibits IR-induced NE-like differentiation. IR-induced NE-like morphologies are reversible, and three IR-resistant clones isolated from dedifferentiated cells have acquired the ability to proliferate and lost the NE-like cell properties. In addition, these three IR-resistant clones exhibit differential responses to IR- and androgen depletion-induced NE-like differentiation. However, they are all resistant to cell death induced by IR and the chemotherapeutic agent docetaxel and to androgen depletion-induced growth inhibition. These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.",
author = "Xuehong Deng and Han Liu and Jiaoti Huang and Liang Cheng and Keller, {Evan T.} and Parsons, {Sarah J.} and Hu, {Chang Deng}",
year = "2008",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-08-2229",
language = "English",
volume = "68",
pages = "9663--9670",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2

T2 - Implications for disease progression

AU - Deng, Xuehong

AU - Liu, Han

AU - Huang, Jiaoti

AU - Cheng, Liang

AU - Keller, Evan T.

AU - Parsons, Sarah J.

AU - Hu, Chang Deng

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors. Although some patients respond well to the treatment, ∼10% of low-risk and up to 60% of high-risk prostate cancer patients experience recurrent tumors. However, the molecular mechanisms underlying tumor recurrence remain largely unknown. Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis. Further analyses revealed that two cyclic AMP-responsive element binding transcription factors, cyclic AMP-response element binding protein (CREB) and activating transcription factor 2 (ATF2), function as a transcriptional activator and a repressor, respectively, of NE-like differentiation and that IR induces NE-like differentiation by increasing the nuclear content of phospho-CREB and cytoplasmic accumulation of ATF2. Consistent with this notion, stable expression of a nonphosphorylatable CREB or a constitutively nuclear-localized ATF2 in LNCaP cells inhibits IR-induced NE-like differentiation. IR-induced NE-like morphologies are reversible, and three IR-resistant clones isolated from dedifferentiated cells have acquired the ability to proliferate and lost the NE-like cell properties. In addition, these three IR-resistant clones exhibit differential responses to IR- and androgen depletion-induced NE-like differentiation. However, they are all resistant to cell death induced by IR and the chemotherapeutic agent docetaxel and to androgen depletion-induced growth inhibition. These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.

AB - Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors. Although some patients respond well to the treatment, ∼10% of low-risk and up to 60% of high-risk prostate cancer patients experience recurrent tumors. However, the molecular mechanisms underlying tumor recurrence remain largely unknown. Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis. Further analyses revealed that two cyclic AMP-responsive element binding transcription factors, cyclic AMP-response element binding protein (CREB) and activating transcription factor 2 (ATF2), function as a transcriptional activator and a repressor, respectively, of NE-like differentiation and that IR induces NE-like differentiation by increasing the nuclear content of phospho-CREB and cytoplasmic accumulation of ATF2. Consistent with this notion, stable expression of a nonphosphorylatable CREB or a constitutively nuclear-localized ATF2 in LNCaP cells inhibits IR-induced NE-like differentiation. IR-induced NE-like morphologies are reversible, and three IR-resistant clones isolated from dedifferentiated cells have acquired the ability to proliferate and lost the NE-like cell properties. In addition, these three IR-resistant clones exhibit differential responses to IR- and androgen depletion-induced NE-like differentiation. However, they are all resistant to cell death induced by IR and the chemotherapeutic agent docetaxel and to androgen depletion-induced growth inhibition. These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=57149095259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149095259&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2229

DO - 10.1158/0008-5472.CAN-08-2229

M3 - Article

C2 - 19047143

AN - SCOPUS:57149095259

VL - 68

SP - 9663

EP - 9670

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -